Kosj Yamoah MD, PhD

What an incredible day celebrating the ribbon-cutting at the @MoffittNews Speros Outpatient Center. I’m thrilled to showcase our Richard M. Schulze Family Foundation Proton Therapy Center, which will bring highly precise proton therapy to patients and expand access to care!

@MoffittRadOnc @MoffittResearch @Yamoah_lab

Coverage of #APCCC26 🇨🇭 by @OncoAlert 🚨 Day One In which patients is metastases-directed therapy without systemic therapy sufficient? Presenter Dr. Kosj Yamoah 🇺🇸 Patient selection criteria for MDT alone Disease characteristics: • OMPC defined as ≤5 metastatic sites by CT/MRI/bone scan, or ≤10 sites if PSMA-PET is used • The metastases are typically limited to lymph node and osseous sites. • Visceral organ involvement is exclusion for MDT alone. Disease state: metachronous or-HSPC Limitations: MDT should not be used without systemic therapies for, - op-CRPC; recommend ADT+ARPI - synchronous om-HSPC, recommend ADT+ARPI+RT to prostate + MDT in select cases #ProstateCancer #ProstateCancerWeek @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @dmukherji @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb

From the Moffitt booth at #AACR26, Greg Sawyer, PhD (@ProfGregSawyer), walks us through how next-generation patient avatar models are evolving to better reflect tumor heterogeneity and the immune environment. #MoffittAACR26 @AACR

Happening now at #AACR26: Eric Padron, MD (@md_padron), discusses the barriers to developing new therapies for chronic myelomonocytic leukemia, highlighting the challenges of studying and treating rare malignancies. #MoffittAACR26 @AACR

From #AACR26, Greg Sawyer, PhD (@ProfGregSawyer), is joined by Brian Ruffell, PhD (@Ruffell_Lab), to discuss targeting myeloid cells, cell death and vaccine response. They also highlight exciting new research on antibody-drug conjugates and strategies to target tumor-driven immune suppression. #MoffittAACR26

Live from #AACR26, Greg Sawyer, PhD (@ProfGregSawyer), and Ghulam Rasool, PhD (@Gxrasool), reflect on AACR’s first plenary session focused on AI and the rapid growth of the field. They highlight how multimodal AI is shaping the future of cancer research, from biomarker discovery to faster, more actionable insights for treatment planning.

Happening now at #AACR26 Clinical Trials Plenary: Jonathan Riess, MD (@riess_md @UCD_Cancer) shares preliminary safety and clinical activity of zoldonrasib (RMC-9805) forKRAS G12D non-small cell lung cancer. Key takeaways: Zoldonrasib (RMC-9805) is an oral, potent, mutant-selective, covalent inhibitor of RAS(ON) G12D. Zoldonrasib is well tolerated and manageable with primarily Grade 1 treatment-related adverse events, no Grade 4 or 5 TRAEs, and high dose intensity. Zoldonrasib has demonstrated encouraging clinical activity at the RPD of 1200 mg QD as measured by ORR, PFS, and preliminary OS in patients with previously treated KRAS G12D NSCLC. Preliminary safety and antitumor activity support the continuing development of zoldonrasib as a single agent, and in combination with other therapies including: • Daraxonrasib (RMC-6236) in solid tumors (NCT06040541) • Standard of care regimens for NSCLC (NCT06162221) • Standard of care regimens for GI cancers (NCT06445062) #MoffittAACR26

While at #AACR26, explore Yuanyuan Shen, MD, PhD (@DrShen_Yy)’s poster on a single-cell atlas that maps tumor cell states and links them to clinical outcomes in head and neck cancer. #MoffittAACR26

At #AACR26, Timothy Yap, MBBS, PhD (@UTMDAnderson) presents Phase I data of the combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations. Key takeaways: • First early clinical proof-of-concept for synthetic lethal combination of WEE1i (zedoresertib) + PKMYTi (lunresertib) in multiple tumor types with CCNE1 amp, FBXW7 mut or PPP2R1A mut tumors. • Zedoresertib + lunresertib is well tolerated and demonstrates strong anti-tumor activity particularly in patients with resistant/refractory ovarian cancer: -Most common TRAES (Mainly Gr. 1/2) were nausea/vomiting, asthenia, anemia, rash and erythema. No clinically relevant myelosuppression has been observed as a safety concern. -In pts with OvCa, 80% showed tumor shrinkage, overall response (RECIST and GCIG CA125) was 37.5% and DCR was 87.5%. Response rate is further enriched in CCNE1 amp pts at the potential RP2D, increasing OR to 6 out of 10 pts (60%). -Molecular response rate of 47% in total population and 67% in patients with ovarian cancer. • Responses observed in patients following progression on or after ADC treatment (e.g. mirvetuximab soravtansine, T-Dxd, T-DM1). • Schedule/dose optimisation in multiple tumor types is currently ongoing. • This oral combination may provide a novel therapeutic option for patients harboring CCNE1 amplification, FBXW7 and PPP2R1A mutations across multiple tumor types with high unmet medical need and based on these data: Zedoresertib + lunresertib has been granted FDA Fast Track Designation in patients with ovarian cancer harboring CCNE1 amplification, FBXW7 or PPP2R1A deleterious mutations. #MoffittAACR26

Live at #AACR26: CID-078, a novel Cyclin A/B-RxL inhibitor, demonstrates promising early clinical activity with a favorable safety profile in advanced solid tumors, presented by Afshin Dowlati, MD (@caseccc). Key takeaways: • Novel oral macrocycle dual cyclin A/B RxL inhibitor. • PK analysis shows linear increases in exposure with dose. • Favorable safety and tolerability profile through highest dose tested as of cut date (720mg BID). -Dose limiting toxicity of ALT increase reported in 1 patient at 300 mg BID and 1 patient at 600 mg BID. -TRAES ≥ Gr. 3 observed in 7 (8.9%) patients with 1 discontinuation due to TRAE at 300mg BID. • Hypothesis that RB1 loss / E2F high tumors will be sensitive to dual-inhibition of cyclin A/B is being evaluated. -Encouraging early signs of anti-tumor activity observed. • Planning to evaluate "RB1-driven/E2F high" tumor types, such as sarcoma, neuroendocrine carcinoma (including SCLC), TNBC, and others, in expansion cohorts. #MoffittAACR26

Following his major symposium presentation at #AACR26, Eric Padron, MD (@md_padron), shares insights on the barriers to developing new therapies for chronic myelomonocytic leukemia. #MoffittAACR26 @AACR

Live from #AACR26: @PatrickHwuMD talks with Ignacio Garrido-Laguna, MD, PhD, MBA, about the promise of early therapeutics, the progress of KRAS-targeted therapies and what this momentum could mean for patients facing some of the toughest cancers. #MoffittAACR26

At #AACR26, Ghulam Rasool, PhD (@Gxrasool), shares how multi-agent AI can extract social determinants of health from unstructured clinical records to better understand patient outcomes over time. #MoffittAACR26 @AACR

Excited to join the world’s leading cancer researchers @AACR @MoffittNews

Today at #AACR26, I spoke with Dr. Greg Sawyer (@ProfGregSawyer), chair of Bioengineering @moffittnews about the growing role of engineering in cancer research. By combining new technologies, AI and advanced tumor models, researchers are creating more precise ways to study cancer and test new treatments, bringing us closer to better outcomes for patients. #AACR26 #MoffittAACR26

While at #AACR26, I spoke with Jason Lebsack, who leads clinical research operations @Moffittnews, about how we’re improving the way clinical trials are activated and delivered. By streamlining processes, strengthening partnerships and using more efficient systems, this work is helping bring new trials to patients faster and more effectively. #AACR26 #MoffittAACR26

From the Moffitt booth at #AACR26, insights from Elsa Flores, PhD (@LabElsaFlores), and Brian Ruffell, PhD (@Ruffell_Lab), on how tumor cells may evade immune recognition through surface molecules, particularly in genomically unstable breast cancers. #MoffittAACR26 @AACR

At his poster during #AACR26, Rolando Trejos, PhD, shares how intersecting identities may shape physical and mental health-related quality of life among LGBTQ+ patients with cancer. #MoffittAACR26 @AACR

From the floor at #AACR26, a conversation between Elsa Flores, PhD (@LabElsaFlores), and Chang Jiang, PhD (@ChangJiangLab), on how cancer metabolism research, including dendritic cell metabolism, may enhance immune responses and improve therapies like CAR T-cell treatment. #MoffittAACR26 @AACR

While at #AACR26, Moffitt’s Keiran Smalley, PhD (@LabSmalley), and Zeynep Eroglu, MD, discuss advances in melanoma research, including tumor-infiltrating lymphocyte therapy and a novel trial using CRISPR-edited TILs. They also highlight ongoing research in rare melanoma subtypes. #MoffittAACR26 @AACR